Richard Mandel, MD
Infectious Disease · Tucson, AZNPI 1841398211
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Astellas Pharma US Inc at 56.2% of the total. Reporting peaked in 2019 at $472 and has fallen 83.0% since, to $80 in 2025.
Across 50 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$782
- Merck$163
- Johnson & Johnson$79
- Viiv Healthcare Company$72
- AbbVie$68
- Insmed, Inc.$58
- plus $169 from 7 others
What the payments were for
- Food & beverage$65147%
- Education$74053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 15 | $782 |
| Merck | 11 | $163 |
| Johnson & Johnson | 4 | $79 |
| Viiv Healthcare Company | 4 | $72 |
| AbbVie(2 entities) | 4 | $68 |
| Insmed, Inc. | 3 | $58 |
| Aimmune Therapeutics, Inc. | 1 | $38 |
| Gilead | 2 | $36 |
| Cumberland Pharmaceuticals, Inc. | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Oxford Immunotec USA Inc | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
How this compares
$1,392 in reported general payments places this provider in the 80th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 14 | $13,469 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Tucson
- Mohanad Al-ObaidiTucson$3K
- Logan FelixTucson$2K
- Sudha NagalingamTucson$2K
- Marcelo NasifTucson$1K
- Steven OscherwitzTucson$1K
- Laura ValdiviaTucson$1K
- Vimbai NyembaTucson$806
- Janin StrumingerTucson$805
- Clifford MartinTucson$775
- Angelita Poston-SeitzTucson$770
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.